Weekly paclitaxel in the treatment of recurrent ovarian cancer

摘要: Weekly paclitaxel is a highly active and well tolerated regimen that increasingly being adopted for the treatment of relapsed ovarian cancer. This usually administered at 80-90 mg/m(2)/week, use 1 h infusion helps minimize myelosuppression. When compared with 3-weekly schedule, weekly better tolerated, reduced frequency grade 3-4 toxic effects. Single-agent cancer yields response rates in range 20-62%; however, duration can be short. Responses to have been observed patients whose tumors are resistant paclitaxel. The level activity disease has led its detailed evaluation first-line setting, interest enhanced by results Japanese Gynecological Oncology Group study demonstrated survival advantage combination carboplatin as initial treatment. efficacy may due greater drug exposure, direct antiangiogenic effect, or both. Current research topics include molecular-targeted agents molecular profiling select